Share buyback program – Ipsen reporting from 22 to 26 August 2022 – Detailled
- 30 August 2022 - 1 mins read
This article or press release has no online content. Please download the associated documents for more information.
Attachment
07 December 2023
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
07 December 2023
10 mins read
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
07 December 2023
5 mins read
Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
14 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
07 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
06 November 2023
1 mins read
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
26 October 2023
7 mins read
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
24 October 2023
1 mins read
IPSEN – Buy-back program – Art 5 of MAR – Week 42 – 2023
23 October 2023
8 mins read